Overview

* Vera Therapeutics ( VERA ) Q2 net loss misses analyst expectations, EPS also missed

* Co reports positive results from ORIGIN Phase 3 trial for atacicept

* Vera plans BLA submission for atacicept in Q4 2025, commercial launch in 2026

Outlook

* Vera plans BLA submission for atacicept in Q4 2025

* Commercial launch of atacicept expected in 2026

* Company to present ORIGIN 3 trial results in Q4 2025

* Initial PIONEER trial results expected in Q4 2025

Result Drivers

* POSITIVE TRIAL RESULTS - Vera reports positive primary endpoint results from ORIGIN Phase 3 trial, with 46% reduction in proteinuria for atacicept-treated patients

* EXPANDED TRIALS - Initiated PIONEER trial to evaluate atacicept in broader IgAN and other autoimmune glomerular diseases

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Miss -$1.2 -$0.82

(12

Analysts

)

Q2 Net Miss -$76.53 -$53.20

Income mln mln (8

Analysts

)

Q2 Miss -$80.14 -$56 mln

Operatin mln (9

g Income Analysts

)

Q2 $80.14

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vera Therapeutics Inc ( VERA ) is $67.50, about 69.7% above its August 4 closing price of $20.45

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)